SCHEMBL3670833

SCHEMBL3670833

CCCCCn1c(O)nc2ncc(Cl)c(CNC(=O)COC)c21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.35
POLB P06746 1/20 0.35
RECQL P46063 1/20 0.35
HPGD P15428 3/20 0.34
ALOX15 P16050 1/20 0.34
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
FAAH O00519 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SMO Q99835 1/20 0.31
MAPT P10636 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3666351 0.87 SMN1; SMN2 (0.39) POLBRECQLLMNATP53PDE4A
SCHEMBL3670831 0.80 BACE1 (0.34) HPGDALOX15LMNATP53PDE4A
SCHEMBL3676625 0.79 TLR8 (0.32)
SCHEMBL3673265 0.78 PLA2G2A (0.39) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL3670906 0.77 TLR7 (0.32)
SCHEMBL3666912 0.75 HTT (0.32) LMNASMN1; SMN2
SCHEMBL3668665 0.75 TLR8 (0.34) RECQLPDE4APDE4BPDE4CPDE4D
SCHEMBL3666998 0.74 KDM4E (0.35) LMNAPDE4APDE4BPDE4CPDE4D
SCHEMBL3670605 0.74 CNR2 (0.34) LMNAPDE4AMAPTCNR1CNR2
SCHEMBL3670329 0.74 TLR8 (0.34) LMNAPDE4BSMN1; SMN2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP disclosed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 TRPV1 1253/4885POLB 721/4885RECQL 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.